Skip to content
Politically.com Search all
Menu

2026 · 1st Quarter (Jan 1 - Mar 31)

HEREDITARY HEMORRHAGIC TELANGIECTASIA FOUNDATION

Filed by CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C..

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
1st Quarter - Report
Posted
Apr 15, 2026
Income
$10,000.00
Expenses
Not reported
Filing UUID
68373fcd-2774-479d-b224-87ebdf29806d
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

DEF · Defense

Hereditary Hemorrhagic Telanglectasia (HHT)

HCR · Health Issues

H.R. 7148, FY 2026 Consolidated Appropriations Act, Peer Reviewed Medical Research Program designation for Hereditary Hemorrhagic Telangiectasia (HHT) and Funding for National HHT Center of Excellence Program; H.R./S. Unnumbered, FY 2027 Defense Appropriations Act, Peer Reviewed Medical Research Program designation for Hereditary Hemorrhagic Telangiectasia (HHT); H.R./S. Unnumbered, FY 2027 Labor-HHS-Education Act, Funding for National HHT Center of Excellence Program

Literal federal measure citations: H.R. 7148

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.